We are live on ! Find out more
PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

Back to rankings

7 hedge funds and large institutions have $32K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more funds holding

Funds holding: 6 → 7 (+1)

2% less capital invested

Capital invested by funds: $32.7K → $32K (-$751)

Holders
7
Holders Change
+1
Holders Change %
+16.67%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AW
Atlas Wealth
Ohio
+$3.39K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
HFBOT
1
Home Federal Bank of Tennessee
Tennessee
$12.6K – – –
AW
2
Atlas Wealth
Ohio
$6.78K +$3.39K +26,620 +100%
LDB
3
Lee, Danner & Bass
Tennessee
$6K +$6K +50,000 New
LIA
4
LBMC Investment Advisors
Tennessee
$2.77K – – –
ACM
5
Academy Capital Management
Texas
$2.52K – – –
FS
6
Financial Symmetry
North Carolina
$1.28K – – –

PVCT Hedge Fund Activity: Q2 2024 in Review

7 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q2 2024, worth a combined $32K — down 2.3% from $32.7K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new PVCT positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Atlas Wealth, adding an estimated $3.39K.

  • 7 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q2 2024, up from 6 in Q1 2024.
  • Funds reported $32K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q2 2024, down 2.3% quarter-over-quarter.
  • 1 fund opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q2 2024 and 0 closed out, a net change of +1 holder.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q2 2024 was Atlas Wealth, an estimated $3.39K added.

Based on aggregated 13F filings for Q2 2024.